• Neurimmune and Ethris to develop mRNA antibody for Covid-19 pharmaceutical-technology
    April 02, 2020
    Swiss biopharmaceutical firm Neurimmune has partnered with German biotechnology company Ethris to develop mRNA-based, neutralising antibodies for a Covid-19 therapeutic formulated for inhalation.
PharmaSources Customer Service